Drugs / HY-0102
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06094777 | Dec 2023 → Jun 2025 | neoplastic disease or syndrome | Shanghai YingLi Pharmaceutical Co. Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04914351 | May 2022 → Nov 2023 | — | Shanghai HyaMab Biotech Co.,Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06662669 | Nov 2024 → Sep 2027 expected | malignant pancreatic neoplasm | Shanghai YingLi Pharmaceutical Co. Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HY-0102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06662669 ↗ |
| Modality | Monoclonal antibody | “HY-0102 is a recombinant anti-NKG2A humanized monoclonal antibody.” NCT06662669 ↗ |
| Route | Intravenous | “HY-0102 administered intravenously (IV) once every two weeks” NCT04914351 ↗ |